{"preliminary_commentary":{"by_channel":{"youtube":2,"podcast":2,"x_thread":2},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":false},"name":"MAPKeeper 301","nct_id":"NCT07562152","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=mapkeeper-301-nct07562152. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"MAPKeeper 301","arms":[{"description":"Atebimetinib in combination with modified gemcitabine and nab-paclitaxel for first line pancreatic adenocarcinoma","label":"Atebimetinib + mGnP","type":"EXPERIMENTAL"},{"description":"Standard of care gemcitabine and nab-paclitaxel for first line pancreatic adenocarcinoma","label":"GnP","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2029-02","type":"ESTIMATED"},"conditions":["Pancreatic Cancer","Pancreatic Cancer Metastatic","PDAC","PDAC - Pancreatic Ductal Adenocarcinoma","Pancreatic Ductal Adenocarcinoma","Pancreatic Adenocarcinoma Metastatic","Pancreatic Ductal Adenocarcinoma (PDAC)","Pancreatic Adenocarcinoma"],"enrollment":{"count":510,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Atebimetinib","otherNames":[],"type":"DRUG"},{"name":"GnP","otherNames":[],"type":"DRUG"},{"name":"mGnP","otherNames":[],"type":"DRUG"}],"last_update":"2026-10-16","lead_sponsor":"Immuneering Corporation","official_title":"A Phase 3 Randomized, Open-Label Study of Atebimetinib in Combination With the Modified Gemcitabine and Nab-Paclitaxel Regimen Versus the Standard Gemcitabine and Nab-Paclitaxel Regimen for the Treatment of Patients With Metastatic Pancreatic Ductal Pancreatic Adenocarcinoma Cancer (MAPKeeper 301)","overall_status":"RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2028-06","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Overall Survival","timeFrame":"Up to approximately 2 years"}],"references":[],"start_date":{"date":"2026-06-05","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma","url":"https://clinicaltrials.gov/study/NCT07562152"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/mapkeeper-301-nct07562152"}